StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2273.HK$26.90-3.58%
Fair $26.90+0.0%

2273.HK

Gushengtang Holdings Limited

Healthcare / Medical Care FacilitiesHKSE

$26.90

-1.00 (-3.58%)

Fairly Valued+0.0%Fair Value $26.90Fund rank 38/100 · Data gapFallback financials|
SA 58/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $361.8M · quality 82.0/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 89/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists.
Thesis & Journal · 2273.HKLocal privado en este navegador · Gushengtang Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.8B

P/E

16.0x

↓

EV/EBITDA

10.1x

↓

ROE

16.3%

↑

Gross Margin

31.2%

↓

Debt/Equity

0.36

↑
52-Week Range$27
$25$39

TradingView lightweight chart

2273.HK price, volumen y niveles de valoración

Último $26.90Periodo -7.2%
Fair value: $26.90

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+26.0%

FCF CAGR

+26.6%

FCF margin

15.2%

FCF / Net income

1.40x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.25B · net income $352.8M · FCF $494.0M

2022-FY → 2025-FY

Gross margin

31.2%+0.4% pts

Operating margin

14.2%+1.7% pts

Net margin

10.9%-0.3% pts

FCF margin

15.2%+0.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.25B$3.25B$3.02B$2.32B$1.62B
Net Income$352.8M$352.8M$306.8M$252.2M$180.9M
EBITDA$637.5M$637.5M$531.9M$429.9M$324.2M
EPS1.451.451.221.030.76
Gross Margin31.2%31.2%30.1%30.1%30.7%
Operating Margin14.2%14.2%12.1%12.0%12.5%
Net Margin10.9%10.9%10.2%10.9%11.1%
Balance Sheet
Debt/Equity0.360.360.210.160.20
Current Ratio1.611.61———
Cash Flow
Free Cash Flow$494.0M$494.0M$361.8M$332.4M$243.5M
Returns
ROE16.3%16.3%12.9%10.9%10.5%
Valuation
P/E16.0116.0125.4545.5862.43
EV/EBITDA10.0810.0813.5124.5133.00
P/B3.013.013.284.976.61
Growth & Yield
Revenue Growth7.5%7.5%30.1%43.0%—
EPS Growth18.9%18.9%18.4%35.5%—
Dividend Yield3.9%3.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

18.1%

exigente

EPS terminal req.

$2.39

Spread vs growth

0.8%

5Y implied EPS CAGR

14.8%

razonable

EPS terminal req.

$2.89

Spread vs growth

4.1%

10Y implied EPS CAGR

12.4%

razonable

EPS terminal req.

$4.65

Spread vs growth

6.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -18.0%

Total return

-18.0%

Start / end P/E

28.2x → 18.6x

EPS bridge

1.22 → 1.45

Residual

-6.5%

EPS growth+18.9%
Multiple rerating-34.3%
Dividend+3.9%
Residual / FX / buybacks / cross-term-6.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.